Cannabinoids in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Randomized Controlled Trials

Key Points

• The review aims to evaluate the effectiveness of cannabinoids for treating chemotherapy-induced peripheral neuropathy (CIPN) through randomized controlled trials.
• Conducted a systematic review of randomized controlled trials evaluating cannabinoids for CIPN.
• Analyzed various study designs, outcome measures, and adverse events.
• Identified challenges in performing a meta-analysis due to heterogeneity.
• Current evidence is insufficient to recommend routine use of cannabinoids for CIPN.
• Adverse events reported included mild to moderate effects like fatigue, dizziness, and dry mouth.
• Recommendations include the need for larger trials with standardized outcomes and longer follow-up.